House
Sign inCreate account
Drug lookup
Drug reference

fam-trastuzumab deruxtecan

antibody-drug conjugate (ADC), HER2-targeted, topoisomerase I inhibitor · anticancer

antibody-drug conjugate (ADC), HER2-targeted, topoisomerase I inhibitoranticancer
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Fam-trastuzumab deruxtecan is an HER2-targeted antibody conjugated to a camptothecin derivative (topoisomerase I inhibitor).

Indications

locally advanced or metastatic HER2-positive breast cancerHER2-positive gastric cancer

Side effects

Serious
  • interstitial lung disease
  • pneumonitis (including fatal cases)
  • cardiotoxicity

Related guidelines

Breast cancer
ESMO · Oncology · 2024
Breast cancer
ICMR · Oncology · 2022
Cervical cancer screening and management
ICMR · Oncology · 2022
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Gastric premalignant conditions
ACG · Gastroenterology · 2025

Ask House about fam-trastuzumab deruxtecan

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team